Growth Hormone Deficiency (GHD) Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | Key Companies - Ascendis Pharma, Novo Nordisk, Lumos Pharma, I-Mab Biopharma

DelveInsight's "Growth Hormone Deficiency Market Insights, Epidemiology, and Market Forecast 2032" report provides comprehensive insights into the disease landscape, encompassing historical and forecasted epidemiological data, along with an analysis of the Growth Hormone Deficiency market. The report offers valuable information regarding market size, share, emerging trends, and growth prospects across the seven major markets (7MM), including the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Additionally, the report delves into emerging therapies for Growth Hormone Deficiency, providing insights into current treatment methodologies, individual therapy market shares, and a comprehensive evaluation of the market size, spanning from 2019 to 2032. It assesses the existing treatment practices and algorithms for Growth Hormone Deficiency, investigates the key factors influencing market growth, identifies barriers, and highlights unmet medical needs. This comprehensive analysis aims to pinpoint opportunities and gauge the market's inherent potential to address the critical aspects of Growth Hormone Deficiency management.

Learn How the Growth Hormone Deficiency Market is Evolving with the Ongoing Developments @ Growth Hormone Deficiency Market Outlook

Growth Hormone Deficiency: An Overview

Growth Hormone Deficiency (GHD) is one of many growth disorders that a child can be born with, or it can develop over time. It can occur in isolation or in association with generalized hypopituitarism. Isolated GHD is usually idiopathic, but about 25% of patients have an identifiable etiology. Congenital causes include abnormalities of the GH-releasing hormone receptor and of the GH1 gene, and certain CNS malformations. Acquired causes include therapeutic radiation of the CNS (high-dose radiation can cause generalized hypopituitarism), meningitis, histiocytosis, and brain injury. Radiation of the spine, either prophylactic or therapeutic, may further impair the growth potential of the vertebrae and further jeopardize height gain.

Sometimes, Growth Hormone Deficiency can be associated with lower levels of other hormones, such as vasopressin (which controls water production in the body), gonadotropins (which controls the production of male and female sex hormones), thyrotropins (which control the production of thyroid hormones) or adrenocorticotrophic hormone (which controls the adrenal gland and related hormones).

Children are usually diagnosed by approximately seven years of age due to short stature and stunted growth velocity, although some children are not diagnosed until delay in pubertal growth spurt. To diagnose GH deficiency, the healthcare providers need to check for conditions such as normal variations of growth, such as familial short stature; other disorders, such as thyroid hormone deficiency or kidney disease, and genetic conditions. Tests like blood tests, X-rays, CT scans, and MRIs may be conducted to diagnose this condition. GH release stimulation tests are often needed to confirm PGHD diagnosis.

Growth Hormone Deficiency Market Key Facts

• An estimated 6,000 adults are diagnosed with growth hormone (GH) deficiency every year in the United States. Adult GH deficiency has been estimated to affect 1 in 100,000 people annually, whereas its incidence is approximately 2 cases per 100,000 population when childhood-onset GH deficiency patients are considered.
• According to D B Allen et al., about 15%-20% of the cases represent the transition of childhood GH deficiency into adulthood.
• As per Jana Bujanova et al., the estimated prevalence of Growth Hormone Deficiency in the UK is approximately 1 in 10,000 (a total of approximately, 6380 patients). If Childhood-onset GH deficiency is added to this number, then prevalence is 1 in 10,000 to 1 in 3500.
• According to the NORD, Growth Hormone Deficiency affects males and females equally. However, given the greater concern for boys with short stature in most societies, diagnosis tends to favor males over females. About 73% of patients with idiopathic Growth Hormone Deficiency in the NCGS were males. Additionally, patients with Growth Hormone Deficiency from organic causes such as tumors and radiation, in which no gender bias should be present, were still 62% males.

Get Exclusive Data and Key Insights Shaping the Market Dynamics @ Growth Hormone Deficiency Market Trends

Growth Hormone Deficiency Therapeutics Analysis

Currently, treatment of Growth Hormone Deficiency is provided in the form of Recombinant Human Growth Hormone (rhGH). It is available as a subcutaneous injection, and the starting dose of GH depends on the age and clinical condition of the patient. For patients with adherence issues, a less frequent dose regimen such as alternate days or 3 times per week using the same total weekly dosage can be used.

Growth Hormone Deficiency in adults is now well-defined both clinically and biochemically. With the advent of recombinant technology, there is now a virtually unlimited, safe supply of recombinant human GH for the treatment of children and adults with Growth Hormone Deficiency. GH deficiency is treated with injections of recombinant growth hormone. Most children receive injections daily; others receive it six times a week; and, a few receive it three times a week There is usually a prompt increase in growth rate after treatment starts, which may be noticeable to the child and parent in 3 to 4 months. This faster-than-normal growth rate slowly declines over time, but it continues to be greater than would occur without treatment.

To improve the treatment scenario, Several major pharma and biotech companies are developing therapies for Growth Hormone Deficiency. Currently, Ascendis Pharma (TransCon hGH/lonapegsomatropin) is leading the therapeutics market with its Growth Hormone Deficiency drug candidates in the most advanced stage of clinical development.

Growth Hormone Deficiency Therapeutic Advancements and Emerging Treatments:

• Growth Hormone Deficiency Clinical Trial Progression and Key Companies: The market is set to experience significant growth, driven by the progression of emerging therapies expected for launch between 2023 and 2032. Pioneering companies, including Ascendis Pharma, Novo Nordisk, Lumos Pharma, I-Mab Biopharma Co. Ltd, and many others, are actively engaged in developing novel drugs for potential market entry.
• Growth Hormone Deficiency Emerging and Marketed Therapies: Ongoing research and development activities are fostering the introduction of innovative therapies designed to address the signs and symptoms of Growth Hormone Deficiency. Some of the emerging therapies in the pipeline include TransCon growth hormone (TransCon hGH) (Ascendis Pharma), Somapacitan (Novo Nordisk), LUM-201 (Lumos Pharma), TJ101 (I-Mab Biopharma Co. Ltd), and many others.

Discover Significant Progress and Start Making Informed Decisions @ Clinical, Commercial, and Regulatory Activities in the Growth Hormone Deficiency Market

Growth Hormone Deficiency Market Growth Factors and Associated Trends

The Growth Hormone Deficiency (GHD) market in the 7MM (Seven Major Markets) showcases a dynamic landscape shaped by a confluence of drivers and barriers. Drivers encompass a multitude of factors propelling the market growth, notably including increasing awareness and diagnosis of GHD cases, advancements in diagnostic tools and technologies, and a rising prevalence of risk factors such as genetic disorders and chronic illnesses. Moreover, a surge in research and development initiatives aimed at novel therapeutic interventions, coupled with a growing emphasis on personalized medicine, fuels the market's expansion. Additionally, the expanding geriatric population and the escalating demand for improved healthcare infrastructure across developed and developing economies contribute to the market's upward trajectory. 

However, barriers persist, posing challenges to the GHD market's growth. These obstacles comprise stringent regulatory frameworks, particularly in drug approvals and clinical trials, along with the high cost associated with GHD treatments, limiting access for certain patient demographics. Furthermore, the complexities involved in accurately diagnosing GHD and the dearth of awareness, particularly in some regions, remain significant hurdles. Despite these challenges, concerted efforts in research, technological innovation, and healthcare policy improvements are pivotal in mitigating barriers and fostering the growth of the GHD market in the 7MM.

Growth Hormone Deficiency Market

The report's market outlook section offers a comprehensive understanding of the historical, present, and projected market size. It scrutinizes the influence of existing and upcoming pipeline therapies for Growth Hormone Deficiency. Moreover, it conducts a thorough evaluation of the factors driving and hindering the Growth Hormone Deficiency market, highlighting unmet needs and emerging technologies poised to shape the market's dynamics in the foreseeable future.

The report meticulously outlines the market trends concerning each marketed Growth Hormone Deficiency drug and mid to late-stage pipeline therapies. This evaluation gauges their impact by considering various aspects such as the annual cost of therapy, Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competitive landscape among therapies, brand value, and their collective influence on the market dynamics.

Discover the Anticipated Evolution and Growth of the Market @ Growth Hormone Deficiency Therapeutics Market Forecast

Growth Hormone Deficiency Epidemiology Assessment 

The epidemiology section offers valuable insights into the historical, present, and anticipated trends in Growth Hormone Deficiency epidemiology across the seven major countries (7MM) from 2019 to 2032. This section aims to identify the factors contributing to current and projected Growth Hormone Deficiency epidemiological patterns by examining diverse studies and research findings. Additionally, it furnishes a comprehensive analysis of diagnosed and prevalent patient populations, and future projections, and incorporates perspectives from key opinion leaders to enrich the understanding of this disease landscape.

The Report Covers the Growth Hormone Deficiency Epidemiology, Segmented as -

• Prevalent Cases of Growth Hormone Deficiency in 7MM [2019–2032]
• Diagnosed Prevalent Cases Based on Onset of GHD [Childhood Onset GHD, Adult Onset GHD] in 7MM [2019–2032]
• Treatable Cases of Growth Hormone Deficiency in the 7MM [2019–2032]
• Gender-specific Prevalent Cases of Growth Hormone Deficiency in 7MM [2019–2032]

Growth Hormone Deficiency Drugs Uptake and Pipeline Development Activities

The drug uptake section concentrates on evaluating the adoption rate of newly launched or upcoming potential drugs within the Growth Hormone Deficiency market during the study period. This analysis encompasses the assessment of drug uptake in the Growth Hormone Deficiency market, patient adoption across different therapies, and the sales performance of each drug. Furthermore, the therapeutics assessment section facilitates a comprehensive comprehension of market dynamics by examining drug sales trends, identifying drugs with the highest adoption rates, and elucidating the reasons contributing to the widespread use of specific medications. Additionally, it conducts comparative analyses among Growth Hormone Deficiency drugs, considering their sales performance and respective market shares.

The report encompasses comprehensive coverage of ongoing Growth Hormone Deficiency pipeline development initiatives. It furnishes valuable insights into diverse therapeutic candidates at various developmental stages, elucidating the significant companies actively engaged in creating targeted treatments for Growth Hormone Deficiency. Moreover, it conducts an in-depth analysis of recent advancements, including collaborations, acquisitions, mergers, licensing details, and patent information, providing a holistic view of emerging therapies within the field.

Reports Key Features and Analysis

• Study Period - 2019-32
• Forecast Period - 2023-32
• Geography Coverage - 7MM (United States, EU4 [Germany, Spain, Italy, France], the United Kingdom, and Japan)
• Market Size (by 2032) and Expected CAGR - Download the Sample PDF
• Major Players Shaping the Market Dynamics - Ascendis Pharma, Novo Nordisk, Lumos Pharma, I-Mab Biopharma Co. Ltd, and many others.
• Emerging and Marketed Therapies Covered in the Report - TransCon growth hormone (TransCon hGH) (Ascendis Pharma), Somapacitan (Novo Nordisk), LUM-201 (Lumos Pharma), TJ101 (I-Mab Biopharma Co. Ltd), and many others.

For In-depth Insights, key Report Offerings TOC, Access the Sample PDF File @ Growth Hormone Deficiency Therapeutics Market Outlook and Forecast

Related Reports:

• Growth Hormone Deficiency (GHD) Epidemiology Forecast

The Growth Hormone Deficiency Epidemiology Forecast report delivers an in-depth understanding of Growth Hormone Deficiency, and historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

• Growth Hormone Deficiency (GHD) Pipeline Insight

The Growth Hormone Deficiency Pipeline Insight report provides comprehensive insights about major pharma and biotech companies and emerging drugs in the Growth Hormone Deficiency pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.

Healthcare Consulting and Market Research Services by DelveInsight

Upgrade your industry insights with our comprehensive medical devices market assessment reports. Visit to gain a strategic edge through expert analysis and in-depth coverage of the latest trends, innovations, and market dynamics @ Healthcare Market Research Services

Elevate your market presence and strategy in the medical devices' industry through our meticulous market research services, driving growth and precision in every decision @ Medical Devices Market

DelveInsight's specialized oncology consulting empowers the pharma and biotech giants with tailored guidance and forefront proficiency, enabling adept navigation of ever-evolving clinical, commercial, and regulatory landscapes. Explore further at @ Oncology Consulting Services

Discover how our tailored methodology ensures real-time evaluation of cancer therapy performance using Lead and Lag KPIs. Download our Oncology Product Assessment Case study!

About DelveInsight:

DelveInsight is a prominent business consultant and market research firm specializing in the life sciences sector. With a focus on supporting pharmaceutical companies, DelveInsight provides end-to-end solutions to enhance their performance.

Contact Information:

Shruti Thakur (Manager, Marketing and IB)

info@delveinsight.com

www.delveinsight.com

Connect with DelveInsight: LinkedIn | Facebook | Twitter